💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Acutaas Chemicals Limited, formerly Ami Organics Limited, is a manufacturer of pharma intermediates and specialty chemicals. It is focused on the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates), New Chemical Entities (NCE) and…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, fast-growing business, priced for perfection.
ACUTAAS CHEMICALS LIMITED is scored on the pharma / healthcare framework. It keeps a fat 25.8% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 0.82×). Free cash flow is worth about 0.1% of its market value.
Over the last 3 years revenue compounded at 31%/yr and profit at 62%/yr. Book value itself has compounded 42%/yr — the hallmark of a genuine compounder. Return on equity is an elite 23.6%. In the latest quarter profit grew 64% versus the prior quarter.
At 87× earnings, the stock sits at the 83rd percentile of its own 3.6-year range — the expensive end of where it has historically traded. Today's price already implies ~26%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 70.68 | — | — |
| P/B | 16.69 | 4.1 | worse |
| EV/EBITDA | 47.35 | 19.33 | worse |
| ROE | 23.64 | — | — |
| ROCE | 32.25 | 14.41 | better |
| ROA | 19.75 | — | — |
| Quick Ratio | 2.82 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 31% CAGR over 3 years — high-growth territory. Growth is decelerating — latest year grew slower than the year before.
Profit is growing faster than revenue (62% vs 31%) — margin expansion is at work. The latest year saw a +122% swing — check if it's a one-off or structural.
Operating margin has expanded from 18% to 35% — the business is keeping more of each rupee earned. The gap between operating and net margin is widening — interest or tax costs are rising.
ROE at 21% — the business earns well above its cost of equity. ROE powered by fat margins — the hallmark of a high-quality franchise with pricing power. Capital efficiency improving — ROE up 7pp across the window.
Profit grew faster than EPS (62% vs 24%) — share dilution is eroding per-share value. 24% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Raising capital despite positive cash flow — could signal expansion plans or opportunistic fundraising.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 33% sequentially — momentum is building. Run-rate fading — recent quarters 8% below earlier ones.
Profit jumped 64% QoQ — check if this is operating leverage or a one-off item.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 32.7% — dispersed ownership; institutional flows drive the stock. FIIs have accumulated for 3 straight quarters — sustained foreign institutional conviction.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.